Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker

G. Perera, M. Ranola, D. B. Rowe, G. M. Halliday, N. Dzamko*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    26 Citations (Scopus)
    5 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker'. Together they form a unique fingerprint.

    Medicine & Life Sciences